The primary goal of the East African IeDEA Consortium (IeDEA-EA) is the provision of answers to questions that clinicians, programs, as well as governmental and international organizations consider fundamental to the evolution and sustainability of their long term HIV care and treatment strategies. The current global focus is on achieving the UNAIDS 90-90-90 targets. As such, our central hypothesis is that retention in the HIV care cascade, as well as outcomes of HIV care and treatment, are influenced by patient-level developmental and behavioral factors along with factors within the ambient healthcare environment. We posit that achievement of the 90-90-90 targets will require examination of these factors and identification of their individual and synergistic roles in influencing engagement in care, ART uptake, retention on treatment and viral suppression. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus extensive experience in sampling-based methodologies and novel analytical approaches.
Specific Aim (SA)-1: This application will continue our work to describe the movement through and outcomes of HIV care and treatment. We will continue to utilize our Clinic Cohort to address questions related to the level of immunodeficiency, co-infections and co-morbidities at enrollment and at ART initiation. We will assess the impact of ART on clinical, immunologic, and virologic outcomes, as the ultimate purpose of the HIV care cascade is to reduce morbidity and mortality. Utilizing established Kaposi's Sarcoma (KS) Sentinel Sites, we describe the changing epidemiology and outcomes of KS in the ART era. We will also begin to address Cervical Cancer as a co-morbidity through an analysis of linked Clinic Cohort and Cervical Cancer screening data. SA-2: To expand our understanding of the factors impacting retention in and outcomes of the HIV care cascade, we will examine the impact of developmental transitions and life stage factors. We will establish an Adolescent Sentinel Cohort, focusing on the impact of adolescence on retention, viral suppression, HIV resistance and mortality while exploring retention and outcomes related to pregnancy within our Clinic Cohort. SA-3: We will examine the impact of behavioral factors on patient outcomes concentrating on the syndemics of substance use and mental illness. We will complete our assessment on the impact of alcohol on treatment outcomes in our Alcohol Use Assessment Cohort and will establish a Sentinel Behavioral Cohort in which we will assess the impact of substance use and mental health on patient outcomes. SA-4: To understand contextual issues of care, we will examine the impact of the health care environment on patient outcomes. We will look at the interactions between clinic-level factors and outcomes and begin to map system-level characteristics, such as the availability of services for adolescents, mental health, and substance abuse. We will pursue this aim within a Provider Sentinel Cohort to enumerate provider characteristics over time and identify those associated with better quality of care and patient outcomes.

Public Health Relevance

Through these efforts, we will enhance our understanding of the HIV care cascades and the outcomes of care in East Africa, provide insights on the optimal structure and impact of care and treatment programs, expand the set of tools available to inform implementation and operations research in resource-constrained settings and inform policy among stakeholders and decision makers at every level in the region as well as the broader HIV/AIDS scientific community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069911-15
Application #
9988344
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Zimand, Lori B
Project Start
2006-08-05
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
15
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Tymejczyk, Olga; Brazier, Ellen; Yiannoutsos, Constantin et al. (2018) HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Med 15:e1002534
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration; Slogrove, Amy L; Schomaker, Michael et al. (2018) The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Med 15:e1002514
Siika, Abraham; McCabe, Leanne; Bwakura-Dangarembizi, Mutsa et al. (2018) Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clin Infect Dis 66:S140-S146
Vreeman, Rachel C; Ayaya, Samuel O; Musick, Beverly S et al. (2018) Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa. PLoS One 13:e0191848
Olney, Jack J; Eaton, Jeffrey W; Braitstein, Paula et al. (2018) Optimal timing of HIV home-based counselling and testing rounds in Western Kenya. J Int AIDS Soc 21:e25142
Holmes, Charles B; Yiannoutsos, Constantin T; Elul, Batya et al. (2018) Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa. PLoS One 13:e0190828
Mukerji, Shibani S; Misra, Vikas; Lorenz, David R et al. (2018) Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. Clin Infect Dis 67:1182-1190
Hakim, James G; Thompson, Jennifer; Kityo, Cissy et al. (2018) Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis 18:47-57
IeDEA and COHERE Cohort Collaborations (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis 66:893-903
Hu, Liangyuan; Hogan, Joseph W; Mwangi, Ann W et al. (2018) Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection. Biometrics 74:703-713

Showing the most recent 10 out of 121 publications